No gene associations or inheritance patterns are certified in the current packet for the broad hereditary angioedema category. The condition encompasses multiple subtypes with distinct underlying causes; recognized subtypes include forms associated with deficiency of a specific regulatory protein as well as forms in which that protein level is normal. Specific genetic variants underlying each subtype are documented at the subtype level.

No diagnostic methods or criteria are certified in the current packet for the broad hereditary angioedema category. Diagnostic approaches are documented at the subtype level.

Four pharmacological treatments with FDA approval and active market status are documented in the current packet for hereditary angioedema: berotralstat hydrochloride (ORLADEYO, approved December 2025), donidalorsen (DAWNZERA, approved August 2025), sebetralstat (EKTERLY, approved July 2025), and garadacimab (ANDEMBRY, approved June 2025).

Natural history data are not certified in the current packet for hereditary angioedema. Prognosis is documented at the subtype level.

Several active clinical trial records are present for hereditary angioedema. Notable studies include a Phase 3 study evaluating NTLA-2002 in participants with hereditary angioedema (NCT06634420, Intellia Therapeutics, active not recruiting), a Phase 3 study of navenibart in participants with hereditary angioedema (NCT06842823, Astria Therapeutics, active not recruiting), and a Phase 4 safety and effectiveness study of sebetralstat for short-term prophylaxis before procedures (NCT07654829, KalVista Pharmaceuticals, not yet recruiting). Active clinical trials for this condition are listed on ClinicalTrials.gov.